AGE insider filings

AgeX Therapeutics, Inc. — 35 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-18. Screen AGE transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for AGE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — AgeX Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2023-05-184Juvenescence Ltd — Director, 10% ownerGrant/award (A): 756,429 (derivative) @ $0EDGAR
2023-03-224Juvenescence Ltd — Director, 10% ownerGift (G): 16,447,500 @ $0EDGAR
2023-03-144WEST MICHAEL D — Chief Executive OfficerOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,060 @ $0.59 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2023-02-174Juvenescence Ltd — Director, 10% ownerGrant/award (A): 801,924 (derivative) @ $0EDGAR
2023-02-084Juvenescence Ltd — Director, 10% ownerGrant/award (A): 340,136 (derivative) @ $0EDGAR
2022-12-194Juvenescence Ltd — Director, 10% ownerGrant/award (A): 847,457 (derivative) @ $0EDGAR
2022-12-134WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.59 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2022-10-274Juvenescence Ltd — Director, 10% ownerGrant/award (A): 362,318 (derivative) @ $0EDGAR
2022-09-134WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.56 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2022-08-244Juvenescence Ltd — Director, 10% ownerGrant/award (A): 746,380 (derivative) @ $0EDGAR
2022-08-244Juvenescence Ltd — Director, 10% ownerGrant/award (A): 703,234 (derivative) @ $0EDGAR
2022-06-144WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.77 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2022-04-144Juvenescence Ltd — Director, 10% ownerGrant/award (A): 568,440 (derivative) @ $0EDGAR
2022-03-154WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,281 @ $0.69 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2022-03-114Juvenescence Ltd — Director, 10% ownerGrant/award (A): 5,230,768 (derivative) @ $0EDGAR
2022-02-144Juvenescence Ltd — 10% ownerPurchase (P): 308,565 (derivative) @ $0EDGAR
2022-02-044Hackett Joanne M. — DirectorGrant/award (A): 65,000 (derivative) @ $0EDGAR
2021-12-144WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.64 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2021-09-214WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $1.00 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2021-06-234Jenkins Annalisa — DirectorGrant/award (A): 65,000 (derivative) @ $0EDGAR
2021-06-234MAY MICHAEL H — DirectorGrant/award (A): 65,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0EDGAR
2021-06-234Bailey Gregory — DirectorGrant/award (A): 65,000 (derivative) @ $0EDGAR
2021-06-154WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $1.53 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2021-06-084STERNBERG HAL — Vice President-ResearchGrant/award (A): 5,000 (derivative) @ $0EDGAR
2021-06-084Park Andrea Eun Jae — Chief Financial OfficerGrant/award (A): 75,000 (derivative) @ $0EDGAR
2021-06-084MALIK NAFEES NASEER — Chief Operating OfficerGrant/award (A): 75,000 (derivative) @ $0EDGAR
2021-06-084WEST MICHAEL D — Chief Executive Officer, DirectorGrant/award (A): 120,000 (derivative) @ $0EDGAR
2021-06-084SEGALL JUDITH — Director of Admin & SecretaryGrant/award (A): 3,000 (derivative) @ $0EDGAR
2021-03-154WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,284 @ $2.03 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2021-02-094Juvenescence Ltd — 10% ownerPurchase (P): 263,852 (derivative) @ $0EDGAR
2021-01-124Juvenescence Ltd — 10% ownerPurchase (P): 328,947 (derivative) @ $0EDGAR
2020-12-154WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $1.69 · Option exercise (M): 3,125 (derivative) @ $0EDGAR
2020-11-194Juvenescence Ltd — 10% ownerPurchase (P): 280,898 (derivative) @ $0EDGAR
2020-10-064Juvenescence Ltd — 10% ownerPurchase (P): 588,235 (derivative) @ $0EDGAR
2020-09-154WEST MICHAEL D — Chief Executive Officer, DirectorOption exercise (M): 3,125 @ $0 · Tax withholding (F): 1,081 @ $0.81 · Option exercise (M): 3,125 (derivative) @ $0EDGAR

Recent 8-K events — AgeX Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-098-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-098-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-278-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-228-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-06-248-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 — Submission of Matters to a Vote of Security Holders
EDGAR
2026-05-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-218-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
EDGAR

Registration filings — AgeX Therapeutics, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs